Abstract:Event Abstract Back to Event A theranostic gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells Qiao Jin1, Haijie Han1, Haibo Wang1 and Jian Ji1 1 Zhejiang University, Department of Polymer Science and Engineering, China Pancreatic cancer is one of the most lethal malignancies with a 5 year survival rate of 5% [1]. Gemcitabine (GEM) is currently the first line drug available for treatment of pancreatic cancer. Unfortunately, the clinical application of GEM is severely limited since it can undergo rapid deamination into inactive metabolite [2]. Meanwhile, in the clinical management of pancreatic cancer patients, timely assessment of therapeutic response to a given therapy is critical for making treatment decisions. A new class of fluorescent probes with aggregation-induced emission (AIE) behaviours was reported as a powerful tool in biosensing and bioimaging [3]. In this research, we designed a novel theranostic tetraphenylene (TPE)-containing gemcitabine prodrug TPE-GEM-RGD, which can be used for targeted light-up imaging and selective release of GEM under intracellular reductive environment (Figure 1). Figure 1. TPE-GEM-RGD for cathepsin B-responsive fluorescence light up and reduction-responsive drug release. In order to evaluate the light-up capability of TPE-GEM-RGD prodrug, the fluorescent spectra of TPE-GEM-RGD incubated with cathepsin B were recorded. The fluorescence intensity of TPE-GEM-RGD increased steadily with time in the presence of cathepsin B, which might be ascribed to the cleavage of GFLG sequence by cathepsin B. The reduction-responsive GEM release was studied by incubating TPE-GEM-RGD prodrug with 10 mM of GSH. According to HPLC analysis, upon treating with GSH, GEM was released owing to the appearance of the peak at 4.3 min, which was the characteristic peak of free GEM. Therefore, GEM can be released upon treating with GSH. Since cathepsin B is overexpressed in pancreatic cancer cells, the capability of TPE-GEM-RGD as cancer cell specific fluorescent light-up probe was studied for live cell imaging [4]. As shown in Figure 2, strong blue fluorescence was observed after BxPC-3 cells were incubated with 50 μM TPE-GEM-RGD. However, when BxPC-3 cells were pretreated with cathepsin B inhibitor CA-074-Me, only very weak blue fluorescence was observed. Moreover, TPE-GEM-RDG prodrug without RGD targeting was used as a negative control. The fluorescent intensity of BxPC-3 cells incubated with TPE-GEM-RDG was much weaker than that incubated with TPE-GEM-RGD. These results demonstrated that the intracellular fluorescence light-up can be achieved. Figure 2. Fluorescent microscopy images of BxPC-3 cells (a) incubated with TPE-GEM-RGD; (b) pretreated with CA-074-Me and incubated with TPE-GEM-RGD; (c) incubated with TPE-GEM-RDG. In order to identify the reduction-responsive release of GEM, the in vitro cell proliferation inhibition behavior was studied by MTT. The GSH level in BxPC-3 cells can be enhanced or inhibited by pretreating the cells with GSH promoterGSH-OEt or GSH inhibitor BSO [5]. As shown in Figure 3,the BxPC-3 cells pretreated with GSH-OEt or BSO exhibited lowest or highest cell viability, which proved the GSH-responsive behavior of TPE-GEM-RGD prodrug. Figure 3. Cell viability of BxPC-3 cells incubated with TPE-GEM-RGD prodrug. BxPC-3 cells were pretreated with BSO or GSH-OEt. In summary, we have successfully synthesized a theranostic TPE-GEM-RGD prodrug with AIE-based intracellular light-up properties. The TPE-GEM-RGD prodrug was used for targeted light-up imaging and selective inhibition of the proliferation of pancreatic cancer cells. References:[1] R. L. Siegel, K. D. Miller and A. Jemal, CA Cancer J. Clin., 2015, 65, 5-29[2] H. Eda, M. Ura, K. FO, Y. Tanaka, M. Miwa and H. Ishitsuka, Cancer Res., 1998, 58, 1165-1169[3] J. Liang, B. Z. Tang and B. Liu, Chem. Soc. Rev., 2015, 44, 2798-2811[4] G. Y. Lee, W. P. Qian, L. Wang, Y. A. Wang, C. A. Staley, M. Satpathy, S. Nie, H. Mao and L. Yang, ACS Nano, 2013, 7, 2078-2089[5] R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen and Z. Zhong, J. Control. Release, 2011, 152, 2-12 Keywords: Drug delivery, theranostic, Imaging method, targeting delivery Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: Poster Topic: Cell-targeting biomaterials in theranostic delivery Citation: Jin Q, Han H, Wang H and Ji J (2016). A theranostic gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.02499 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Qiao Jin Haijie Han Haibo Wang Jian Ji Google Qiao Jin Haijie Han Haibo Wang Jian Ji Google Scholar Qiao Jin Haijie Han Haibo Wang Jian Ji PubMed Qiao Jin Haijie Han Haibo Wang Jian Ji Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

A Cascade Enzymatic Reaction Activatable Gemcitabine Prodrug with an AIE-based Intracellular Light-Up Apoptotic Probe for in Situ Self-Therapeutic Monitoring

Real-time Monitoring of Cell Apoptosis and Drug Screening Using Fluorescent Light-Up Probe with Aggregation-Induced Emission Characteristics.

The Rational Design of a Gemcitabine Prodrug with AIE-based Intracellular Light-Up Characteristics for Selective Suppression of Pancreatic Cancer Cells.

Targeted Theranostic Platinum(Iv) Prodrug With A Built-In Aggregation-Induced Emission Light-Up Apoptosis Sensor For Noninvasive Early Evaluation Of Its Therapeutic Responses In Situ

A Theranostic Gemcitabine Prodrug with AIE-based Intracellular Light-Up Characteristics for Selective Suppression of Pancreatic Cancer Cells

Cascade-Activated AIEgen-Peptide Probe for Noninvasively Monitoring Chymotrypsin-like Activity of Proteasomes in Cancer Cells

Light-up Bioprobe with Aggregation-Induced Emission Characteristics for Real-Time Apoptosis Imaging in Target Cancer Cells.

Theranostic Reduction-Sensitive Gemcitabine Prodrug Micelles for Near-Infrared Imaging and Pancreatic Cancer Therapy

Folate Receptor-Targeted and Cathepsin B-Activatable Nanoprobe for in Situ Therapeutic Monitoring of Photosensitive Cell Death

Enzyme‐Mediated Intracellular Polymerization of AIEgens for Light‐Up Tumor Localization and Theranostics

Light‐Up Probe for Targeted and Activatable Photodynamic Therapy with Real‐Time In Situ Reporting of Sensitizer Activation and Therapeutic Responses

A Sequential Enzyme-Activated and Light-Triggered Pro-Prodrug Nanosystem for Cancer Detection and Therapy.

A cathepsin B-sensitive gemcitabine prodrug for enhanced pancreatic cancer therapy

Multifunctional Gold Nanoclusters-Based Nanosurface Energy Transfer Probe for Real-Time Monitoring of Cell Apoptosis and Self-Evaluating of Pro-Apoptotic Theranostics.

Nanomized Tumor-Microenvironment-active NIR Fluorescent Prodrug for Ensuring Synchronous Occurrences of Drug Release and Fluorescence Tracing

A Biocompatible And Cathepsin B Sensitive Nanoscale System Of Dendritic Polyhpma-Gemcitabine Prodrug Enhances Antitumor Activity Markedly

A Camptothecin Prodrug Induces Mitochondria-Mediated Apoptosis in Cancer Cells with Cascade Activations.

Image-guided Combination Chemotherapy and Photodynamic Therapy Using a Mitochondria-Targeted Molecular Probe with Aggregation-Induced Emission Characteristics

Intracellular Dual Fluorescent Lightup Bioprobes for Image-Guided Photodynamic Cancer Therapy.

Supramolecular Aggregation-Induced Emission Nanodots with Programmed Tumor Microenvironment Responsiveness for Image-Guided Orthotopic Pancreatic Cancer Therapy.

Mitochondria-targeted Pt(IV) Prodrugs Conjugated with an Aggregation-Induced Emission Luminogen Against Breast Cancer Cells by Dual Modulation of Apoptosis and Autophagy Inhibition.